MinervaX provides clinical and leadership update

by | Oct 7, 2021

MinervaX, a privately held Danish biotechnology company developing a novel vaccine against Group B Streptococcus (GBS), today announces clinical progress on its maternal GBS vaccine as well as multiple additions to its leadership teams. MinervaX is developing a maternal vaccine for the prevention of adverse pregnancy outcomes and lifethreatening infections caused by Group B streptococcus (GBS). 

Press inquiries should be adressed to:

Sten Verland, PhD MSc

General Partner